Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 6/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894201 | 0.93 | PDGFRA (0.49) | PDGFRAPDGFRBMETFGFR2KDR | |
| SCHEMBL3398093 | 0.85 | EGFR (0.50) | PDGFRAPDGFRBKDRKIT | |
| Ammonia Solution, Strong SCHEMBL2063727 | 0.82 | FGFR2 (0.63) | PDGFRAPDGFRBFGFR2KDRKIT | |
| SCHEMBL4465629 | 0.81 | FGFR2 (0.68) | PDGFRAPDGFRBMETFGFR2KDR | |
| SCHEMBL10296328 | 0.81 | KDM1A (0.56) | PDGFRAPDGFRBFGFR2 | |
| SCHEMBL6592222 | 0.81 | KDM1A (0.56) | PDGFRAPDGFRBFGFR2 | |
| SCHEMBL31678916 | 0.81 | FGFR2 (0.61) | PDGFRAPDGFRBMETFGFR2KDR | |
| SCHEMBL14098962 | 0.81 | FGFR2 (0.61) | PDGFRAPDGFRBMETFGFR2KDR | |
| SCHEMBL2064387 | 0.81 | FGFR2 (0.61) | PDGFRAPDGFRBMETFGFR2KDR | |
| SCHEMBL24520223 | 0.80 | KDR (0.53) | PDGFRAPDGFRBMETFGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | PDGFRA 36/4885PDGFRB 16/4885MET 17/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | PDGFRA 32/4885PDGFRB 14/4885MET 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.